Interestingly, the latest advances in AMD research also highlight common moleculardisease pathways with other neurodegenerative disorders.
2
Thus, there is a high clinical need for moleculardisease biomarkers to aid in differentiating these distinct phenotypes.
3
These cells remain after IM therapy, even when apparently complete responses are achieved, and they probably explain moleculardisease persistence.
4
These patients are typically younger and suffer from conditions caused by a known moleculardisease mechanism and a peculiar sarcopenic phenotype.
5
Fluorogenic probes that signal the presence of specific DNA or RNA sequences are key enabling tools for moleculardisease diagnosis and imaging studies.
6
Here, we performed whole exome sequencing in 79 consanguineous or familial cases of suspected nephronophthisis in order to determine the underlying moleculardisease cause.
7
Moleculardisease mechanisms downstream of functional SMN loss are still largely unknown.